All In Biotech

Drug Trial Radar · NCT00471237

A Phase II Study Evaluating SB-751689 in Post-Menopausal Women With Osteoporosis.

Study CR9108963: A 12-month, Randomized, Double-blind, Parallel-group, Placebo and Active-controlled Dose-range Finding Study of the Efficacy and Safety of SB-751689 in Post-menopausal Women With Osteoporosis

Last checked: Nov 20, 2026Latest source record: Nov 7, 2017 (this record)Source: ClinicalTrials.govMethods & limitations

TerminatedResults posted on the registryPivotal-lookingRandomized with 564 participants. This is a heuristic, not a regulatory label.

Status

Terminated

Enrollment

564

Actual

Start

May 14, 2007

Primary completion

Dec 26, 2008

Study completion Dec 26, 2008

Sponsor

Lead sponsor
GlaxoSmithKlineGSK (GSK)
Sponsor type
Industry
First posted
May 9, 2007

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Parallel
Masking
Triple (participant, investigator, outcomes assessor)
Primary purpose
Treatment
Who can join
Female only, from 18 years, up to 79 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This is a 12 month study designed to evaluate the safety and effectiveness of SB-751689 in the treatment of osteoporosis in post-menopausal women, in comparison with 2 active comparators and placebo.

Conditions

  • Osteoporosis

Interventions

  • RonacaleretDrug

    100mg, 200mg, 300mg, 400mg

  • TeriparatideDrug

    PTH (1-34)

  • AlendronateDrug

    Bisphosphonate

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Percent Change From Baseline in Bone Marrow Density (BMD) at Month 12 Measured by Dual-Energy X-Ray Absorptiometry (DXA) Scans of the Lumbar Spine (L1-L4)Time frame: Baseline (Day 0) and 12 Months
  2. Number of Participants With HypercalcemiaTime frame: Up to Month 12
  3. Number of Participants Withdrew Due to HypercalcemiaTime frame: Up to Month 12
  4. Number of Participant With Laboratory Abnormalities of Potential Clinical Concern at Any Post-baseline VisitTime frame: Up to Month 12
  5. Number of Participant With Vital Signs of Potential Clinical Concern at Any Post-baseline VisitTime frame: Up to 12 Months
  6. Number of Participant With Electrocardiogram (ECG) Findings Reported as Adverse EventTime frame: Up to 12 months
  7. Mean Change From Baseline in HeightTime frame: Baseline (Day 0), Month 6, 12 and early withdrawal
  8. Mean Change From Baseline in WeightTime frame: Baseline (Day 0), Month 6, 12 and early withdrawal

Locations

49 sites in 14 countries. Site status is shown where the registry gives one.

  • GSK Investigational Site

    Oakland, California

  • GSK Investigational Site

    Palm Desert, California

  • GSK Investigational Site

    Walnut Creek, California

  • GSK Investigational Site

    Decatur, Georgia

  • GSK Investigational Site

    Bethesda, Maryland

  • GSK Investigational Site

    Akron, Ohio

  • GSK Investigational Site

    Cleveland, Ohio

  • GSK Investigational Site

    Portland, Oregon

  • GSK Investigational Site

    Duncansville, Pennsylvania

  • GSK Investigational Site

    Buenos Aires, Argentina

  • GSK Investigational Site

    Buenos Aires, Argentina

  • GSK Investigational Site

    Ciudad Autónoma de Buenos Aires, Buenos Aires, Argentina

  • GSK Investigational Site

    St Leonards, New South Wales, Australia

  • GSK Investigational Site

    Footscray, Victoria, Australia

  • GSK Investigational Site

    Geelong, Victoria, Australia

  • GSK Investigational Site

    Heidelberg, Victoria, Australia

  • GSK Investigational Site

    Ghent, Belgium

  • GSK Investigational Site

    Liège, Belgium

  • GSK Investigational Site

    Tienen, Belgium

  • GSK Investigational Site

    Ballerup Municipality, Denmark

  • GSK Investigational Site

    Berlin, Germany

  • GSK Investigational Site

    Berlin, Germany

  • GSK Investigational Site

    Berlin, Germany

  • GSK Investigational Site

    Berlin, Germany

  • GSK Investigational Site

    Hamburg, Germany

  • GSK Investigational Site

    Hamburg, Germany

  • GSK Investigational Site

    Frankfurt am Main, Hesse, Germany

  • GSK Investigational Site

    Hong Kong, Hong Kong

  • GSK Investigational Site

    Shatin, Hong Kong

  • GSK Investigational Site

    Mexico City, Mexico

  • GSK Investigational Site

    Bergen, Norway

  • GSK Investigational Site

    Hamar, Norway

  • GSK Investigational Site

    Oslo, Norway

  • GSK Investigational Site

    Grudziądz, Poland

  • GSK Investigational Site

    Warsaw, Poland

  • GSK Investigational Site

    Wroclaw, Poland

  • GSK Investigational Site

    Moscow, Russia

  • GSK Investigational Site

    Moscow, Russia

  • GSK Investigational Site

    Panorama, South Africa

  • GSK Investigational Site

    Rosebank, South Africa

Showing 40 of 49 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.